Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Atalanta Therapeutics
The company sees aducanumab adding a modest boost to sales if approved, but there are another four Phase III programs with some major read-outs coming.
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy